Last updated: 15 October 2026. Programme facts checked against FDA sources on that date.
A national priority voucher can cut an FDA drug review from around ten months to one or two. The Commissioner’s National Priority Voucher (CNPV) is an FDA pilot programme rather than a statutory pathway. Its target of one to two months is the shortest review clock the agency offers. Almost a year after the first awards, the pilot has produced ten approvals and one rejection. It has also drawn questions from lawmakers, former officials and parts of the industry it was built to help. This guide explains how the voucher works, who holds one, what has been approved and what could change.
- 22 publicly identified vouchers
- 10 approvals listed by the FDA
- 1 complete response letter
What is a national priority voucher?
The FDA announced the CNPV on 17 June 2025, under then Commissioner Marty Makary. It gives a selected application a target review of one to two months once the final application is in. A standard review takes around 10 to 12 months, and a priority review takes six. The FDA’s programme page says the pilot “is being explored as a pathway to dramatically reduce review times.”
The voucher attaches to a specific application. FDA answers from February 2026 say vouchers “are non-transferable; however, they remain valid through changes in company ownership.” The FDA expects the voucher process to “generally be initiated within two years” of issue.
Congress did not create the programme. The FDA cites its general authority under federal drug and biologics law instead. That choice sits at the root of the legal debate covered below.
To qualify, a product must align with one of five national priorities listed by the FDA:
- public health crisis response
- innovative breakthrough therapies
- large unmet medical needs
- onshoring and supply chain resilience
- affordability
The June 2025 launch release named four goals. Affordability appears on the current programme page.
The scope covers drug and biological product applications, including manufacturing or efficacy supplements and certain combination products. Companies can submit a statement of interest. FDA review divisions can also nominate products already under review. In February 2026, the FDA said it was “now primarily focused on implementation of the pilot.” It still accepts statements of interest.
How an FDA national priority voucher review works
Speed comes from front-loading the work. Sponsors submit chemistry, manufacturing and controls data and draft labelling at least 60 days before the complete application. The lead time rises to 120 days if foreign inspections are expected. Reviewers then work from a near-complete file.
The process runs in four stages:
- Pre-submission: manufacturing data and draft labelling, 60 or 120 days ahead.
- Filing review: a proposed 14 to 21 days after the final component arrives.
- Application review: a target of approximately one to two months.
- Action: approval or a complete response letter from the relevant FDA centre.
During the review, a senior panel called the CNPV Review Council meets with the review team. The FDA’s Federal Register notice describes a “tumor board style” discussion. The council votes by simple majority of members present. The commissioner chairs it but “will not vote on discussions relating to approvability.” That rule comes from the FDA Staff Manual Guide that took effect on 15 January 2026.
The FDA’s FAQs describe the council’s recommendation as non-binding. The Center Director must give a written rationale, whether or not the council agrees. The FDA says final approval decisions stay with its centres.
The clock is a target, not a promise. The launch release reserved the right to extend a review if a submission is incomplete or pivotal results are ambiguous.
National priority voucher vs priority review voucher
The names are similar, but the programmes differ in origin, value and effect. A priority review voucher was created by Congress, buys a six-month review and can be sold. A national priority voucher targets one to two months and cannot be transferred. Congress reauthorised the rare paediatric disease programme in February 2026.
On 7 October 2026, Ultragenyx announced the sale of a rare paediatric disease priority review voucher. The undisclosed buyer is paying $210 million. A national priority voucher has no resale value by design.
The voucher also sets only the clock. Accelerated approval changes the evidence standard, so a single product can use both. Hernexeos and Otarmeni each did so. Standard and priority reviews run against a PDUFA date, the user fee goal date set at filing.
| Programme | Review clock | Created by | Transferable | What it changes |
|---|---|---|---|---|
| National priority voucher (CNPV) | Target of 1 to 2 months | FDA, as a pilot | No | Review speed |
| Priority review voucher | 6 months | Congress | Yes, and can be sold | Faster review for another product |
| Priority review | 6 months | User fee framework | Not applicable | Review speed |
| Standard review | 10 to 12 months | User fee framework | Not applicable | Baseline |
| Accelerated approval | Unchanged | FDA rule, later statute | Not applicable | Evidence standard |
| Breakthrough therapy and fast track designations | Unchanged | Congress | Not applicable | Development support |
National priority voucher recipients: 22 awards since October 2025
The FDA has announced voucher awards in five rounds since 16 October 2025. It stated a total of 18 on 1 April 2026, and three more followed on 24 April. The FDA did not announce a separate award for Bizengri, but listed its May 2026 approval under the pilot. That gives 22 publicly identified vouchers.
The list runs from an established antibiotic to gene therapies and two obesity medicines. Three psychedelic programmes joined on 24 April 2026, six days after a presidential executive order on serious mental illness. The FDA did not name those companies. Fierce Biotech reported them as Compass Pathways, the Usona Institute and Transcend Therapeutics. All three confirmed their awards.
| Award date | Vouchers | Products as named by the FDA |
|---|---|---|
| 16 Oct 2025 | 9 | Pergoveris, teplizumab, cytisinicline, DB-OTO, cenegermin-bkbj, RMC-6236 (daraxonrasib), bitopertin, ketamine, Augmentin XR |
| 6 Nov 2025 | 6 | Zongertinib, bedaquiline, dostarlimab, Casgevy, orforglipron, Wegovy |
| 15 Dec 2025 | 1 | Teclistamab plus daratumumab, awarded after Phase 3 results |
| 19 Dec 2025 | 2 | Enlicitide, sacituzumab tirumotecan |
| 24 Apr 2026 | 3 | Psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, methylone for PTSD |
| By May 2026 | 1 | Bizengri, confirmed through its FDA approval release |
National priority voucher approvals so far
Ten approvals in under nine months looks like a strong record. The detail is more mixed.
National priority voucher approvals listed by the FDA, as of 26 August 2026:
| # | Action date | Product | Sponsor | Review time per FDA | Note |
|---|---|---|---|---|---|
| 1 | 9 Dec 2025 | Augmentin XR (amoxicillin-clavulanate) | USAntibiotics | Two months | US-made antibiotic |
| 2 | 26 Feb 2026 | Hernexeos (zongertinib) | Boehringer Ingelheim | 44 days | Accelerated approval |
| 3 | 5 Mar 2026 | Tec-Dara (teclistamab plus daratumumab) | Janssen Biotech | 55 days | Combination in myeloma |
| 4 | 19 Mar 2026 | Wegovy HD (semaglutide 7.2 mg) | Novo Nordisk | 54 days | Higher dose |
| 5 | 1 Apr 2026 | Foundayo (orforglipron) | Eli Lilly | 50 days | First NME under the pilot |
| 6 | 23 Apr 2026 | Otarmeni (lunsotogene parvec-cwha) | Regeneron | 61 days | Accelerated approval |
| 7 | 8 May 2026 | Bizengri (zenocutuzumab-zbco) | Partner Therapeutics | Not stated | New indication |
| 8 | 1 Jul 2026 | Casgevy (exagamglogene autotemcel) | Vertex | 53 days | Sickle cell and beta thalassaemia, now age 2 and over |
| 9 | 17 Jul 2026 | Lipfendra (enlicitide) | Merck | Not stated | First oral PCSK9 inhibitor, per FDA |
| 10 | 26 Aug 2026 | Rasonque (daraxonrasib) | Revolution Medicines | Not stated | First in class, per FDA |
Where the FDA gave a figure, reviews took between 44 and 61 days after filing. The FDA called Foundayo “the fastest approval of an NME since 2002.” It was issued 50 days after filing and 294 days before its PDUFA date of 20 January 2027. FDA Oncology Center of Excellence director Angelo de Claro said Rasonque was approved 6.5 months before its user fee deadline.
Product type also changes the picture. By LSDN’s reading of FDA releases, four approvals were products new to the US market: Foundayo, Otarmeni, Lipfendra and Rasonque. The other six extended medicines already approved in some form. They cover a new dose, a new combination, new indications, a younger age group and a US-made antibiotic.
The evidence base matters too. Hernexeos and Otarmeni received accelerated approval, which requires further confirmatory evidence. Bizengri was approved on a single-arm trial of 19 patients, with an overall response rate of 36.8 per cent. Foundayo carries a boxed warning for thyroid C-cell tumours.
One voucher holder has been turned down. Disc Medicine received a complete response letter for bitopertin on 13 February 2026. According to Disc, the FDA questioned whether reductions in the biomarker PPIX would translate into clinical benefit. Disc expects an updated decision by mid-2027, after its confirmatory Phase 3 APOLLO trial. The FDA’s staff manual is explicit: “Receipt of a voucher does not impact the likelihood of approval.”
Why the programme is contested
Criticism falls into four groups: legal footing, selection, political proximity and reviewer sign-off. None of it has stopped the programme. All of it bears on how long the voucher lasts in its current form.
Legal footing
Other FDA voucher programmes were created by Congress. For this one, the FDA’s Federal Register notice cites its general authority instead. In a letter dated 3 February 2026, Representative Jake Auchincloss challenged that basis. His letter listed claims for the FDA to confirm or refute. One read: “The FFDCA and the PHSA do not provide the FDA authority to establish the CNPV program as written.”
At the public hearing on 4 June 2026, PhRMA’s Kelly Falconer Goldberg asked the FDA to consider notice-and-comment rulemaking. She also argued that the programme functions as an expedited review mechanism rather than a voucher. No court has ruled on the question.
Selection
The FDA’s staff manual states that for voucher selection, “No formal voting, ranking, or consensus determination is required or expected.” A delegated official makes the final decision. In written comments, the Center for Science in the Public Interest (CSPI) criticised the selection process. It said it was “unable to establish a reason for FDA granting a voucher for 13 of the 22 drugs.” CSPI urged the agency to wind down the pilot.
Political proximity
Affordability is one of the five priorities, although price sits outside the FDA’s traditional approval criteria. The Pergoveris voucher was announced on 16 October 2025, alongside a White House event on fertility drug costs. At that event, EMD Serono announced discounts on its fertility medicines. President Trump said Pergoveris “would directly compete against a much more expensive option.” Auchincloss’s letter also questioned the authority to award vouchers based on post-approval drug pricing.
Reviewer sign-off
In January 2026, the Associated Press reported that senior officials had declined to sign off on voucher approvals. It cited legal concerns and relied largely on current and former staff speaking anonymously. HHS spokesman Andrew Nixon told the AP that voucher submissions are evaluated by “a senior, multidisciplinary review committee.” He added that reviewers can “adjust timelines as needed.”
The case for the programme
Sponsors that have used the voucher broadly support it. At the June hearing, Johnson & Johnson’s Ginny Beakes-Read described “a highly collaborative review process.” Merck’s Ashley Wivel said “success in the pilot has come through earlier structured scientific engagement.” RAPS reported most speakers were “supportive of the intent and goals of the program.” Patient voices pulled in different directions. A Huntington’s disease advocate asked for vouchers to cover breakthrough therapies for the condition. The United Porphyrias Association described the bitopertin rejection as a “crushing blow” and asked for a more patient-informed process.
What happens next for the national priority voucher
Three things will decide the voucher’s future: leadership, paperwork and Congress.
Leadership comes first. Makary resigned on 12 May 2026, and Kyle Diamantas has led the agency as acting commissioner since. An HHS spokesperson responded in May. The spokesperson told Fierce Biotech of “no change to the name or direction of the CNPV program at this time.” President Trump announced on 19 August 2026 that he would nominate Heidi Overton. She appeared before the Senate HELP Committee on 24 September. The committee had not voted by early October. STAT reported no vote is expected before the Senate returns on 9 November.
Paperwork is second. In February 2026, the FDA said it planned additional documentation, such as draft guidance, “in the coming months.” LSDN found no draft guidance published as of 15 October 2026. The comment docket, FDA-2026-N-2366, closed on 29 June.
Congress is third. User fee authority under PDUFA VII expires in September 2027. The proposed PDUFA VIII commitment letter went to a public meeting on 16 September 2026. RAPS reported that a proposed fee cut for US Phase 1 data builds on the pilot.
Several voucher decisions are pending. GSK said on 24 August 2026 that Jemperli for dMMR/MSI-H locally advanced rectal cancer had been accepted for priority review. The PDUFA date is in February 2027, although GSK said the voucher could bring a decision sooner. Compass Pathways expects to complete its rolling submission for COMP360 in the fourth quarter of 2026. Upcoming actions are tracked in LSDN’s FDA drug approval decisions tracker.
What it means for sponsors outside the US
The voucher is a US tool, but its effects travel. A one to two month FDA review can put a US decision well ahead of European and UK timelines. Two of its five priorities, onshoring and affordability, reward US manufacturing and pricing commitments. That matters to any UK or European sponsor planning a global filing sequence.
European-headquartered companies already hold vouchers. FDA releases name Boehringer Ingelheim for Hernexeos and Novo Nordisk for Wegovy HD.
Frequently asked questions
What is a national priority voucher?
It is an FDA pilot launched in June 2025, known in full as the Commissioner’s National Priority Voucher. It gives selected drug and biologic applications a target review of one to two months. Products must align with one of five national priorities.
How long does a CNPV review take?
The target is one to two months after the final application is submitted, against six months for priority review. Where the FDA has published a figure, reviews have taken 44 to 61 days from filing. The agency can extend a review.
Is a national priority voucher the same as a priority review voucher?
No. Priority review vouchers were created by Congress, can be sold and deliver a six-month review. The national priority voucher is an FDA pilot, cannot be transferred and targets one to two months.
Can a national priority voucher be sold?
No. The FDA says the voucher is non-transferable, although it remains valid if the company changes ownership.
Does a national priority voucher guarantee approval?
No. The FDA’s staff manual states that receiving a voucher does not affect the likelihood of approval. Disc Medicine’s bitopertin held a voucher and received a complete response letter in February 2026.
